tiprankstipranks
ValiRx PLC (GB:VAL)
LSE:VAL
Holding GB:VAL?
Track your performance easily

ValiRx plc (VAL) Income Statement

3 Followers

ValiRx plc Income Statement

Last quarter (Q2 2022), ValiRx plc's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, ValiRx plc's net income was £―. See ValiRx plc’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
-----£ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
-£ 2.59M£ 1.68M£ 1.53M£ 2.70M£ 4.37M
Operating Income
-£ -2.59M£ -1.68M£ -1.53M£ -2.70M£ -4.37M
Net Non Operating Interest Income Expense
-£ -5.46K£ 2.77K£ 14.88K£ 21.18K£ -14.56K
Other Income Expense
------
Pretax Income
-£ -2.60M£ -1.68M£ -1.54M£ -2.72M£ -4.83M
Tax Provision
-£ -192.67K£ -133.41K£ -75.18K£ -293.74K£ -461.30K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-£ -2.37M£ -1.52M£ -1.44M£ -2.39M£ -4.30M
Basic EPS
-£ -0.03£ -0.02£ -0.04£ -41.25£ -1.18
Diluted EPS
-£ -0.03£ -0.02£ -0.04£ -41.25£ -1.18
Basic Average Shares
-£ 77.30M£ 65.00M£ 37.90M£ 57.77K£ 3.67M
Diluted Average Shares
-£ 77.30M£ 65.00M£ 37.90M£ 57.77K£ 3.67M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
-----£ 138.62K
Total Expenses
-£ 2.59M£ -1.68M£ -1.53M£ -2.70M£ 4.37M
Net Income From Continuing And Discontinued Operation
-£ -2.37M£ -1.52M£ -1.44M£ -2.39M£ -4.30M
Normalized Income
-£ -2.79M£ -1.81M£ -1.62M£ -3.01M£ -3.90M
Interest Expense
-----£ 866.00
EBIT
-£ -2.59M£ -1.68M£ -1.54M£ -2.72M£ -4.83M
EBITDA
-£ -2.59M£ -1.68M£ -1.54M£ -2.72M£ -4.69M
Currency in GBP

ValiRx plc Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis